Your browser doesn't support javascript.
loading
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease.
Lubbe, S J; Escott-Price, V; Brice, A; Gasser, T; Pittman, A M; Bras, J; Hardy, J; Heutink, P; Wood, N M; Singleton, A B; Grosset, D G; Carroll, C B; Law, M H; Demenais, F; Iles, M M; Bishop, D T; Newton-Bishop, J; Williams, N M; Morris, H R.
Afiliação
  • Lubbe SJ; Department of Clinical Neuroscience, UCL Institute of Neurology, London, United Kingdom.
  • Escott-Price V; Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Brice A; INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle Epinière, ICM, France.
  • Gasser T; Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, and DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany.
  • Pittman AM; Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
  • Bras J; Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
  • Hardy J; Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
  • Heutink P; Department of Clinical Genetics, Section of Medical Genomics, VU University Medical Centre, Amsterdam, The Netherlands.
  • Wood NM; Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom; UCL Genetics Institute, London, United Kingdom.
  • Singleton AB; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
  • Grosset DG; Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Carroll CB; Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.
  • Law MH; Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Demenais F; INSERM, UMR 946, Genetic Variation and Human Diseases Unit, Paris, France; Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne, Paris, France.
  • Iles MM; Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom.
  • Bishop DT; Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom.
  • Newton-Bishop J; Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, Leeds, United Kingdom.
  • Williams NM; Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Morris HR; Department of Clinical Neuroscience, UCL Institute of Neurology, London, United Kingdom. Electronic address: h.morris@ucl.ac.uk.
Neurobiol Aging ; 48: 222.e1-222.e7, 2016 12.
Article em En | MEDLINE | ID: mdl-27640074
ABSTRACT
A shared genetic susceptibility between cutaneous malignant melanoma (CMM) and Parkinson's disease (PD) has been suggested. We investigated this by assessing the contribution of rare variants in genes involved in CMM to PD risk. We studied rare variation across 29 CMM risk genes using high-quality genotype data in 6875 PD cases and 6065 controls and sought to replicate findings using whole-exome sequencing data from a second independent cohort totaling 1255 PD cases and 473 controls. No statistically significant enrichment of rare variants across all genes, per gene, or for any individual variant was detected in either cohort. There were nonsignificant trends toward different carrier frequencies between PD cases and controls, under different inheritance models, in the following CMM risk genes BAP1, DCC, ERBB4, KIT, MAPK2, MITF, PTEN, and TP53. The very rare TYR p.V275F variant, which is a pathogenic allele for recessive albinism, was more common in PD cases than controls in 3 independent cohorts. Tyrosinase, encoded by TYR, is the rate-limiting enzyme for the production of neuromelanin, and has a role in the production of dopamine. These results suggest a possible role for another gene in the dopamine-biosynthetic pathway in susceptibility to neurodegenerative Parkinsonism, but further studies in larger PD cohorts are needed to accurately determine the role of these genes/variants in disease pathogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Neoplasias Cutâneas / Variação Genética / Predisposição Genética para Doença / Estudos de Associação Genética / Melanoma Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Neoplasias Cutâneas / Variação Genética / Predisposição Genética para Doença / Estudos de Associação Genética / Melanoma Idioma: En Ano de publicação: 2016 Tipo de documento: Article